Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
豊田 実*; 解良 恭一*; 大島 康宏; 石岡 典子; 紫野 正人*; 坂倉 浩一*; 高安 幸弘*; 高橋 克昌*; 富永 英之*; 織内 昇*; et al.
British Journal of Cancer, 110(10), p.2506 - 2513, 2014/05
被引用回数：106 パーセンタイル：95.25(Oncology)Amino-acid transporters are necessary for the tumor cell growth and survival, and play a crucial role in the development of cancer. But, it remains unclear about the prognostic significance of L-type amino acid transporter 1 (LAT1), System ASC amino acid transporter 2 (ASCT2) and xCT expression in patients with tongue cancer. We conducted the clinicopathological study to investigate the protein expression of these amino acid transporters in tongue cancer. Eighty-five patients with surgically resected tongue cancer were evaluated. Tumor sections were stained by immunohistochemistry for LAT1, ASCT2, xCT, CD98, Ki-67, CD34 and p53. The expression of LAT1 and ASCT2 was significantly associated with disease staging, lymph node metastasis, lymphatic permeation, vascular invasion, CD98 expression and cell proliferation (Ki-67). xCT expression indicated a significant association with advanced stage and tumor factor, correlated with CD98. By univariate analysis, both LAT1 and ASCT2 had a significant relationship with prognosis. Multivariate analysis confirmed that LAT1 were independent prognostic factors for predicting poor prognosis. These results suggest that LAT1 and ASCT2 can serve as a significant prognostic factor for predicting worse outcome after surgical treatment and may play an important role in the development and pathogenesis for tongue cancer.
解良 恭一*; 須納瀬 豊*; 大島 康宏; 石岡 典子; 荒川 和久*; 小川 哲史*; 砂長 則明*; 清水 公裕*; 富永 英之*; 織内 昇*; et al.
BMC Cancer, 13, p.482_1 - 482_12, 2013/10
被引用回数：74 パーセンタイル：89(Oncology)The expression of L-type amino acid transporter 1 (LAT1) has been described to play essential roles in tumor growth and survival. However, it remains unclear about the clinicopathological significance of LAT1 expression in biliary tract cancer. This study was conducted to determine clinical significance of LAT1 expression and investigate whether LAT1 could be a new therapeutic target for biliary tract cancer. A total of 139 consecutive patients with resected pathologic stage I-IV biliary tract adenocarcinoma were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, CD98, Ki-67, microvessel density determined by CD34 and p53. Further, anti-tumor activity of LAT inhibitor, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) was investigated using cholangiocarcinoma cell line. The expression of LAT1 was recognized in 64% of total patients, and closely correlated with CD98 expression, lymphatic metastases, cell proliferation and angiogenesis, and was a significant indicator for predicting poor outcome after surgery. Experiments showed that BCH significantly suppressed the tumor growth and BCH yielded an additive therapeutic efficacy to gemcitabine and 5-FU. A cooperative high expression of LAT1 with CD98 is a promising pathological marker to predict the outcome in biliary tract adenocarcinoma. Inhibition of LAT1 may be an effective targeted therapy for this distressing disease.
金井 豊*; 奥山 康子*; 瀬尾 俊弘; 坂巻 幸雄*
Geochemical Journal, 32(6), p.351 - 366, 1998/12
被引用回数：10 パーセンタイル：25.92(Geochemistry & Geophysics)東濃ウラン鉱床を胚胎する層準の規定にある花崗岩起起源の風化推積物を採取し、そのウラン系列核種について、粒度分析と分別溶解法を適用して検討した。ウランは細粒部分に濃集しており、雲母量と相関が見られた。分別溶解法によって得られた溶出ウラン量は、全ウラン量の半分以上を占め、特に酢酸ナトリウム/酢酸(pH5.0)のフラクションと塩酸ヒドロキシルアミン/硝酸のフラクションで多く抽出しており炭酸塩や鉄水和物が重要であることを示唆した。イオン交換態のウランのうU-234/U-238放射能は1よりも大きく、周りの地下水の放射能が1より大きいことと調和的であった。珪酸塩部分の放射能比は粗粒試料で大きくなっており、反跳によるinjection効果が優勢で、逆に細粒試料では反跳によるejection効果が優勢であることが判明した。炭酸塩フラクションや鉄酸化物フラクション、有機・酸化物フラクションでは1より小さ
松田 慎三郎; 秋場 真人; 荒木 政則; 大楽 正幸; 海老沢 昇; 堀池 寛; 伊藤 孝雄; 金井 文雄*; 河合 視己人; 小又 将夫; et al.
Fusion Engineering and Design, 5, p.85 - 100, 1987/00
被引用回数：23 パーセンタイル：87.78(Nuclear Science & Technology)JT-60NBI加熱装置のシステムと特徴についてまとめたものである。
解良 恭一*; 豊田 実*; 大島 康宏; 織内 昇*; 金井 好克*; 小山 徹也*; 山田 正信*; 浅尾 高行*; 近松 一朗*
no journal, ,
This study was conducted to determine biological significance of L-type amino acid transporter 1 (LAT1) expression and investigate whether LAT1 could be a prognostic biomarker for tongue cancer. Eighty-five patients with surgically resected tongue cancer were evaluated. Tumor sections were stained by immunohistochemistry for LAT1, ASCT2, xCT, CD98, CD147, Ki-67, microvessel density determined by CD34, and p53. Biological significance of LAT1 expression was investigated by 
experiments with LAT inhibitor, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) using tongue cell line. LAT1, ASCT2, xCT, CD98 and CD147 were highly expressed in 61%, 59%, 21%, 45% and 33%, respectively. The expression of LAT1 was significantly associated with disease staging, lymph node metastasis, lymphatic permeation, cell proliferation (Ki-67), and the expression level of CD98, ASCT2 and CD147 as amino acid transporter complexes. Multivariate analysis confirmed that LAT1 was an independent prognostic factor for predicting poor prognosis. 
preliminary experiment indicated that BCH significantly suppressed growth of the tumor and yielded an additive therapeutic efficacy to cisplatin. These rusults suggests that LAT1 can serve as a promising pathological marker to predict the outcome in patients with tongue cancer. Inhibition of LAT1 may be an effective targeted therapy for this distressing disease.
